I-Patent Entsha YaseJapan Yokugomela Umdlavuza We-Ovarian

“Siyajabula ukumemezela lokhu kuvikelwa kwempahla eqanjiwe yomuthi wokugomela umdlavuza we-ovary ka-Anixa, owakhiwa eCleveland Clinic futhi usafundelwa e-NCI. Lobu buchwepheshe obuyingqayizivele bunamandla okuba umuthi wokuqala wokugoma ukuvimbela umdlavuza wesibeletho, osalokhu ungomunye wezifo zomdlavuza ezibhubhisa kakhulu futhi okunzima ukuwelapha, "kusho uDkt Amit Kumar, i-CEO, uMongameli kanye noSihlalo we-Anixa Biosciences. “Uma uphumelela, lo mgomo ungavimbela umdlavuza wesibeletho ukuthi ungenzeki futhi uphephise iziguli ekutholeni ukwelashwa ngamakhemikhali nokwelashwa okubanzi, futhi okungenzeka usindise izimpilo. Sibheke ngabomvu ukuqhubeka nomsebenzi wethu wokwelapha ngethemba lokuthi lo mgomo uzokwengeza izikhali ezidingekayo ukuze uqondise lo mdlavuza oyinselele futhi ekugcineni wenze umehluko ezigulini eziningi.”

Umuthi wokugomela umdlavuza wesibeletho uqondise kusizinda se-extracellular se-anti-Müllerian hormone receptor 2 (AMHR2-ED), evezwa kuma-ovari kodwa inyamalala njengoba owesifazane efinyelela futhi ethuthuka ngokunqamuka kokuya esikhathini. Okuqaphelekayo, iningi lokuxilongwa komdlavuza wesibeletho kwenzeka ngemva kokunqamuka kokuya esikhathini, futhi i-AMHR2-ED iphinde ivezwe kuningi lomdlavuza wesibeletho. Ngokuthola umuthi wokugoma ofana noka-Anixa oqondise i-AMHR2-ED ngemva kokunqamuka kokuya esikhathini, umdlavuza wesibeletho, ngokomlando ongomunye wemidlavuza yezifo zabesifazane oyingozi kakhulu, ungavinjelwa ukuthi uthuthuke.

Umsebenzi wangaphambi komtholampilo wokuqhubekisela phambili umgomo uyaqhubeka ngoHlelo Lwe-PREVENT ku-National Cancer Institute (NCI), olusekela ukungenelela okusungulwe kwangaphambili kanye nama-biomarker okuvimbela nokuvimbela umdlavuza. Idatha ye-preclinical eshicilelwe kuCancer Prevention Research ngo-2017 isekela ukuqhubekela phambili okuqhubekayo ezifundweni zemitholampilo.